Current procedures for managing polycystic ovary syndrome

References

• Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J. Clin. Endocrinol. Metab.85(7), 2434–2438 (2000).
   PubMed Web of Science ®Google Scholar
• Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J. Clin. Endocrinol. Metab.83(9), 3078–3082 (1998).
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Kouli CR, Bergiele AT et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J. Clin. Endocrinol. Metab.84(11), 4006–4011 (1999).
   PubMed Web of Science ®Google Scholar
• Michelmore KF, Balen AH, Dunger DB, Vessey MP. Polycystic ovaries and associated clinical and biochemical features in young women. Clin. Endocrinol. (Oxf.)51(6), 779–786 (1999).
   PubMed Web of Science ®Google Scholar
• Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J. Clin. Endocrinol. Metab.89(6), 2745–2749 (2004).
   PubMed Web of Science ®Google Scholar
• Executive summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA285(19), 2486–2497(2001).
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism52(7), 908–915 (2003).
   PubMed Web of Science ®Google Scholar
• Vural B, Caliskan E, Turkoz E, Kilic T, Demirci A. Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. Hum. Reprod.20(9), 2409–2413 (2005).
   PubMed Web of Science ®Google Scholar
• Gambineri A, Pelusi C, Manicardi E et al. Glucose intolerance in a large cohort of mediterranean women with polycystic ovary syndrome: phenotype and associated factors. Diabetes53(9), 2353–2358 (2004).
   PubMed Web of Science ®Google Scholar
• Weerakiet S, Srisombut C, Bunnag P, Sangtong S, Chuangsoongnoen N, Rojanasakul A. Prevalence of Type 2 diabetes mellitus and impaired glucose tolerance in Asian women with polycystic ovary syndrome. Int. J. Gynaecol. Obstet.75(2), 177–184 (2001).
   PubMed Web of Science ®Google Scholar
• Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for Type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J. Clin. Endocrinol. Metab.84(1), 165–169 (1999).
   PubMed Web of Science ®Google Scholar
• Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care22(1), 141–146 (1999).
   PubMed Web of Science ®Google Scholar
• Legro RS, Gnatuk CL, Kunselman AR, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J. Clin. Endocrinol. Metab.90(6), 3236–3242 (2005).
   PubMed Web of Science ®Google Scholar
• Cascella T, Palomba S, De Sio I et al. Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndrome. Hum. Reprod.23(1), 153–159 (2008).
   PubMed Web of Science ®Google Scholar
• Shroff R, Kerchner A, Maifeld M, Van Beek EJ, Jagasia D, Dokras A. Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis. J. Clin. Endocrinol. Metab.92(12), 4609–4614 (2007).
   PubMed Web of Science ®Google Scholar
• Lakhani K, Hardiman P, Seifalian AM. Intima–media thickness of elastic and muscular arteries of young women with polycystic ovaries. Atherosclerosis175(2), 353–359 (2004).
   PubMed Web of Science ®Google Scholar
• Talbott EO, Zborowski JV, Rager JR, Boudreaux MY, Edmundowicz DA, Guzick DS. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.89(11), 5454–5461 (2004).
   PubMed Web of Science ®Google Scholar
• Orio F Jr, Palomba S, Cascella T et al. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.89(9), 4588–4593 (2004).
   PubMed Web of Science ®Google Scholar
• Solomon CG, Hu FB, Dunaif A et al. Menstrual cycle irregularity and risk for future cardiovascular disease. J. Clin. Endocrinol. Metab.87(5), 2013–2017 (2002).
   PubMed Web of Science ®Google Scholar
• Yildiz BO, Knochenhauer ES, Azziz R. Impact of obesity on the risk for polycystic ovary syndrome. J. Clin. Endocrinol. Metab.93(1), 162–168 (2008).
   PubMed Web of Science ®Google Scholar
• Yildirim B, Sabir N, Kaleli B. Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome. Fertil. Steril.79(6), 1358–1364 (2003).
   PubMed Web of Science ®Google Scholar
• Rebuffe-Scrive M, Cullberg G, Lundberg PA, Lindstedt G, Bjorntorp P. Anthropometric variables and metabolism in polycystic ovarian disease. Horm. Metab. Res.21(7), 391–397 (1989).
   PubMed Web of Science ®Google Scholar
• Svendsen PF, Nilas L, Madsbad S, Holst JJ. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin. Metabolism58(5), 586–593 (2009).
   PubMed Web of Science ®Google Scholar
• Pehlivanov B, Mitkov M. Serum leptin levels correlate with clinical and biochemical indices of insulin resistance in women with polycystic ovary syndrome. Eur. J. Contracept. Reprod. Health Care14(2), 153–159 (2009).
   PubMed Web of Science ®Google Scholar
• Gambarin-Gelwan M, Kinkhabwala SV, Schiano TD, Bodian C, Yeh HC, Futterweit W. Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin. Gastroenterol. Hepatol.5(4), 496–501 (2007).
   PubMed Web of Science ®Google Scholar
• Thomson RL, Buckley JD, Noakes M, Clifton PM, Norman RJ, Brinkworth GD. The effect of a hypocaloric diet with and without exercise training on body composition, cardiometabolic risk profile, and reproductive function in overweight and obese women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.93(9), 3373–3380 (2008).
   PubMed Web of Science ®Google Scholar
• Aubuchon M, Laughbaum N, Poetker A, Williams D, Thomas M. Supervised short-term nutrition and exercise promotes weight loss in overweight and obese patients with polycystic ovary syndrome. Fertil. Steril.91(4 Suppl.), 1336–1338 (2009).
   PubMed Web of Science ®Google Scholar
• Hoeger K, Davidson K, Kochman L, Cherry T, Kopin L, Guzick DS. The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J. Clin. Endocrinol. Metab.93(11), 4299–4306 (2008).
   PubMed Web of Science ®Google Scholar
• Pasquali R, Antenucci D, Casimirri F et al. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J. Clin. Endocrinol. Metab.68(1), 173–179 (1989).
   PubMed Web of Science ®Google Scholar
• Huber-Buchholz MM, Carey DGP, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J. Clin. Endocrinol. Metab.84(4), 1470–1474 (1999).
   PubMed Web of Science ®Google Scholar
• Hoeger KM. Role of lifestyle modification in the management of polycystic ovary syndrome. Best Pract. Res. Clin. Endocrinol. Metab.20(2), 293–310 (2006).
   PubMed Web of Science ®Google Scholar
• Despres JP, Lemieux I, Prud’homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ322(7288), 716–720 (2001).
   PubMed Web of Science ®Google Scholar
• Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med.346(6), 393–403 (2002).
   PubMed Web of Science ®Google Scholar
• Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of Type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med.344(18), 1343–1350 (2001).
   PubMed Web of Science ®Google Scholar
• Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent Type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia49(2), 289–297 (2006).
   PubMed Web of Science ®Google Scholar
• Pan XR, Li GW, Hu YH et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care20(4), 537–544 (1997).
   PubMed Web of Science ®Google Scholar
• Panidis D, Farmakiotis D, Rousso D, Kourtis A, Katsikis I, Krassas G. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels. Fertil. Steril.89(4), 899–906 (2008).
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Katsikis I, Piperi C, Alexandraki K, Panidis D. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome. Clin. Endocrinol. (Oxf.)66(1), 103–109 (2007).
   PubMed Web of Science ®Google Scholar
• Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of Type 2 diabetes in obese patients. Diabetes Care27(1), 155–161 (2004).
   PubMed Web of Science ®Google Scholar
• Lindholm A, Bixo M, Bjorn I et al. Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Fertil. Steril.89(5), 1221–1228 (2008).
   PubMed Web of Science ®Google Scholar
• Jayagopal V, Kilpatrick ES, Holding S, Jennings PE, Atkin SL. Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. J. Clin. Endocrinol. Metab.90(2), 729–733 (2005).
   PubMed Web of Science ®Google Scholar
• Nader S, Diamanti-Kandarakis E. Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis. Hum. Reprod.22(2), 317–322 (2007).
   PubMed Web of Science ®Google Scholar
• Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception62(1), 29–38 (2000).
   PubMed Web of Science ®Google Scholar
• Rabe T, Kowald A, Ortmann J, Rehberger-Schneider S. Inhibition of skin 5 α-reductase by oral contraceptive progestins in vitro. Gynecol. Endocrinol.14(4), 223–230 (2000).
   PubMed Web of Science ®Google Scholar
• van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis69(4 Suppl.), 2–15 (2002).
   PubMedGoogle Scholar
• Batukan C, Muderris II. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism. Fertil. Steril.85(2), 436–440 (2006).
   PubMed Web of Science ®Google Scholar
• Guido M, Romualdi D, Giuliani M et al. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J. Clin. Endocrinol. Metab.89(6), 2817–2823 (2004).
   PubMed Web of Science ®Google Scholar
• Escobar-Morreale HF, Lasuncion MA, Sancho J. Treatment of hirsutism with ethinyl estradiol-desogestrel contraceptive pills has beneficial effects on the lipid profile and improves insulin sensitivity. Fertil. Steril.74(4), 816–819 (2000).
   PubMed Web of Science ®Google Scholar
• Soares GM, Vieira CS, de Paula MW, Dos Reis RM, de Sa MF, Ferriani RA. Metabolic and cardiovascular impact of oral contraceptives in polycystic ovary syndrome. Int. J. Clin. Pract.63(1), 160–169 (2009).
   PubMed Web of Science ®Google Scholar
• Sanchez LA, Perez M, Centeno I, David M, Kahi D, Gutierrez E. Determining the time androgens and sex hormone-binding globulin take to return to baseline after discontinuation of oral contraceptives in women with polycystic ovary syndrome: a prospective study. Fertil. Steril.87(3), 712–714 (2007).
   PubMed Web of Science ®Google Scholar
• Sahin Y, Dilber S, Kelestimur F. Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism. Fertil. Steril.75(3), 496–500 (2001).
   PubMed Web of Science ®Google Scholar
• Kelestimur F, Sahin Y. Comparison of Diane 35 and Diane 35 plus spironolactone in the treatment of hirsutism. Fertil. Steril.69(1), 66–69 (1998).
   PubMed Web of Science ®Google Scholar
• Odlind V, Milsom I, Persson I, Victor A. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet. Gynecol. Scand.81(6), 482–490 (2002).
   PubMed Web of Science ®Google Scholar
• Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case–control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet346(8990), 1575–1582 (1995).
   PubMed Web of Science ®Google Scholar
• van Hylckama V, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case–control study. BMJ339, b2921 (2009).
   PubMedGoogle Scholar
• Bottiger LE, Boman G, Eklund G, Westerholm B. Oral contraceptives and thromboembolic disease: effects of lowering oestrogen content. Lancet1(8178), 1097–1101 (1980).
   PubMed Web of Science ®Google Scholar
• Vandenbroucke JP, Rosing J, Bloemenkamp KW et al. Oral contraceptives and the risk of venous thrombosis. N. Engl. J. Med.344(20), 1527–1535 (2001).
   PubMed Web of Science ®Google Scholar
• Franchini M, Targher G, Montagnana M, Lippi G. The metabolic syndrome and the risk of arterial and venous thrombosis. Thromb. Res.122(6), 727–735 (2008).
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Paoletti AM, Renzi A et al. Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel. J. Clin. Endocrinol. Metab.88(8), 3621–3625 (2003).
   PubMed Web of Science ®Google Scholar
• Mastorakos G, Koliopoulos C, Deligeoroglou E, Diamanti-Kandarakis E, Creatsas G. Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome. Fertil. Steril.85(2), 420–427 (2006).
   PubMed Web of Science ®Google Scholar
• Dahlgren E, Landin K, Krotkiewski M, Holm G, Janson PO. Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome. Hum. Reprod.13(10), 2706–2711 (1998).
   PubMed Web of Science ®Google Scholar
• Korytkowski MT, Mokan M, Horwitz MJ, Berga SL. Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.80(11), 3327–3334 (1995).
   PubMed Web of Science ®Google Scholar
• Vrbikova J, Stanicka S, Dvorakova K et al. Metabolic and endocrine effects of treatment with peroral or transdermal oestrogens in conjunction with peroral cyproterone acetate in women with polycystic ovary syndrome. Eur. J. Endocrinol.150(2), 215–223 (2004).
   PubMed Web of Science ®Google Scholar
• Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J. Clin. Endocrinol. Metab.85(9), 3161–3168 (2000).
   PubMed Web of Science ®Google Scholar
• Nader S, Riad-Gabriel MG, Saad MF. The effect of a desogestrel-containing oral contraceptive on glucose tolerance and leptin concentrations in hyperandrogenic women. J. Clin. Endocrinol. Metab.82(9), 3074–3077 (1997).
   PubMed Web of Science ®Google Scholar
• Godsland IF. Biology: risk factor modification by OCs and HRT lipids and lipoproteins. Maturitas47(4), 299–303 (2004).
   PubMed Web of Science ®Google Scholar
• Barkfeldt J, Virkkunen A, Dieben T. The effects of two progestogen-only pills containing either desogestrel (75 microg/day) or levonorgestrel (30 microg/day) on lipid metabolism. Contraception64(5), 295–299 (2001).
   PubMed Web of Science ®Google Scholar
• Oelkers WK. Effects of estrogens and progestogens on the renin–aldosterone system and blood pressure. Steroids61(4), 166–171 (1996).
   PubMed Web of Science ®Google Scholar
• Oelkers W. Drospirenone, a progestogen with antimineralocorticoid properties: a short review. Mol. Cell. Endocrinol.217(1–2), 255–261 (2004).
   PubMed Web of Science ®Google Scholar
• WHO. Medical Eligibility Criteria for Contraceptive Use (3rd Edition). WHO, Geneva, Switzerland (2004).
   Google Scholar
• Luque-Ramirez M, Mendieta-Azcona C, Alvarez-Blasco F, Escobar-Morreale HF. Effects of metformin versus ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome. Fertil. Steril.91(6), 2527–2536 (2008).
   PubMed Web of Science ®Google Scholar
• Yilmaz M, Bukan N, Ersoy R et al. Glucose intolerance, insulin resistance and cardiovascular risk factors in first degree relatives of women with polycystic ovary syndrome. Hum. Reprod.20(9), 2414–2420 (2005).
   PubMed Web of Science ®Google Scholar
• Talbott E, Clerici A, Berga SL et al. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case–control study. J. Clin. Epidemiol.51(5), 415–422 (1998).
   PubMed Web of Science ®Google Scholar
• Lo JC, Feigenbaum SL, Yang J, Pressman AR, Selby JV, Go AS. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J. Clin. Endocrinol. Metab.91(4), 1357–1363 (2006).
   PubMed Web of Science ®Google Scholar
• Baillargeon JP, McClish DK, Essah PA, Nestler JE. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J. Clin. Endocrinol. Metab.90(7), 3863–3870 (2005).
   PubMed Web of Science ®Google Scholar
• Giallauria F, Orio F, Palomba S, Lombardi G, Colao A, Vigorito C. Cardiovascular risk in women with polycystic ovary syndrome. J. Cardiovasc. Med. (Hagerstown)9(10), 987–992 (2008).
   PubMed Web of Science ®Google Scholar
• Costello MF, Shrestha B, Eden J, Johnson NP, Sjoblom P. Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review. Hum. Reprod.22(5), 1200–1209 (2007).
   PubMed Web of Science ®Google Scholar
• Yildiz BO. Oral contraceptives in polycystic ovary syndrome: risk–benefit assessment. Semin. Reprod. Med.26(1), 111–120 (2008).
   PubMed Web of Science ®Google Scholar
• Use of insulin-sensitizing agents in the treatment of polycystic ovary syndrome. Fertil. Steril.90(5 Suppl.), S69–S73 (2008).
   Web of Science ®Google Scholar
• Mathur R, Alexander CJ, Yano J, Trivax B, Azziz R. Use of metformin in polycystic ovary syndrome. Am. J. Obstet. Gynecol.199(6), 596–609 (2008).
   PubMed Web of Science ®Google Scholar
• Fux OC, Wior M, Iraci GS et al. Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double-blind, and placebo control trial. Gynecol. Endocrinol.8, 1–6 (2009).
   Google Scholar
• Nieuwenhuis-Ruifrok AE, Kuchenbecker WK, Hoek A, Middleton P, Norman RJ. Insulin sensitizing drugs for weight loss in women of reproductive age who are overweight or obese: systematic review and meta-analysis. Hum. Reprod. Update15(1), 57–68 (2009).
   PubMed Web of Science ®Google Scholar
• Maciel GA, Soares Junior JM, Alves da Motta EL, Abi HM, de Lima GR, Baracat EC. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertil. Steril.81(2), 355–360 (2004).
   PubMed Web of Science ®Google Scholar
• Onalan G, Goktolga U, Ceyhan T, Bagis T, Onalan R, Pabuccu R. Predictive value of glucose-insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic? Eur. J. Obstet. Gynecol. Reprod. Biol.123(2), 204–211 (2005).
   PubMed Web of Science ®Google Scholar
• Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE. Effects of metformin and rosiglitazone, alone and in combination, in lean women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil. Steril.82(4), 893–902 (2004).
   PubMed Web of Science ®Google Scholar
• Sharma ST, Wickham EP III, Nestler JE. Changes in glucose tolerance with metformin treatment in polycystic ovary syndrome: a retrospective analysis. Endocr. Pract.13(4), 373–379 (2007).
   PubMedGoogle Scholar
• Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ327(7421), 951–953 (2003).
   PubMed Web of Science ®Google Scholar
• Kashyap S, Wells GA, Rosenwaks Z. Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome. Hum. Reprod.19(11), 2474–2483 (2004).
   PubMed Web of Science ®Google Scholar
• Creanga AA, Bradley HM, McCormick C, Witkop CT. Use of metformin in polycystic ovary syndrome: a meta-analysis. Obstet. Gynecol.111(4), 959–968 (2008).
   PubMed Web of Science ®Google Scholar
• Baillargeon JP, Iuorno MJ, Nestler JE. Insulin sensitizers for polycystic ovary syndrome. Clin. Obstet. Gynecol.46(2), 325–340 (2003).
   PubMed Web of Science ®Google Scholar
• Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil. Steril.73(6), 1149–1154 (2000).
   PubMed Web of Science ®Google Scholar
• Ibanez L, Valls C, Ferrer A, Marcos MV, Rodriguez-Hierro F, de Zegher F. Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. J. Clin. Endocrinol. Metab.86(8), 3595–3598 (2001).
   PubMed Web of Science ®Google Scholar
• Loverro G, Lorusso F, De Pergola G, Nicolardi V, Mei L, Selvaggi L. Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome. Gynecol. Endocrinol.16(3), 217–224 (2002).
   PubMed Web of Science ®Google Scholar
• Kazerooni T, Dehghan-Kooshkghazi M. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome. Gynecol. Endocrinol.17(1), 51–56 (2003).
   PubMed Web of Science ®Google Scholar
• Aruna J, Mittal S, Kumar S, Misra R, Dadhwal V, Vimala N. Metformin therapy in women with polycystic ovary syndrome. Int. J. Gynaecol. Obstet.87(3), 237–241 (2004).
   PubMed Web of Science ®Google Scholar
• Kriplani A, Agarwal N. Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome. J. Reprod. Med.49(5), 361–367 (2004).
   PubMed Web of Science ®Google Scholar
• Marcondes JA, Yamashita SA, Maciel GA, Baracat EC, Halpern A. Metformin in normal-weight hirsute women with polycystic ovary syndrome with normal insulin sensitivity. Gynecol. Endocrinol.23(5), 273–278 (2007).
   PubMed Web of Science ®Google Scholar
• Cicek MN, Bala A, Celik C, Akyurek C. The comparison of clinical and hormonal parameters in PCOS patients treated with metformin and GnRH analogue. Arch. Gynecol. Obstet.268(2), 107–112 (2003).
   PubMedGoogle Scholar
• Harborne L, Fleming R, Lyall H, Sattar N, Norman J. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J. Clin. Endocrinol. Metab.88(9), 4116–4123 (2003).
   PubMed Web of Science ®Google Scholar
• Gambineri A, Pelusi C, Genghini S et al. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin. Endocrinol. (Oxf.)60(2), 241–249 (2004).
   PubMed Web of Science ®Google Scholar
• Ganie MA, Khurana ML, Eunice M, Gulati M, Dwivedi SN, Ammini AC. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study. J. Clin. Endocrinol. Metab.89(6), 2756–2762 (2004).
   PubMed Web of Science ®Google Scholar
• Yilmaz M, Karakoc A, Toruner FB et al. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. Gynecol. Endocrinol.21(3), 154–160 (2005).
   PubMed Web of Science ®Google Scholar
• Ortega-Gonzalez C, Luna S, Hernandez L et al. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.90(3), 1360–1365 (2005).
   PubMed Web of Science ®Google Scholar
• Meyer C, McGrath BP, Teede HJ. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care30(3), 471–478 (2007).
   PubMed Web of Science ®Google Scholar
• Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in Type II diabetes: results of a double-blind, placebo-controlled, dose–response trial. Am. J. Med.103(6), 491–497 (1997).
   PubMed Web of Science ®Google Scholar
• Bruno RV, de Avila MA, Neves FB, Nardi AE, Crespo CM, Sobrinho AT. Comparison of two doses of metformin (2.5 and 1.5 g/day) for the treatment of polycystic ovary syndrome and their effect on body mass index and waist circumference. Fertil. Steril.88(2), 510–512 (2007).
   PubMed Web of Science ®Google Scholar
• Hellmuth E, Damm P, Molsted-Pedersen L. Oral hypoglycaemic agents in 118 diabetic pregnancies. Diabetic Medicine17(7), 507–511 (2000).
   PubMed Web of Science ®Google Scholar
• Rowan JA, Hague WM, Gao W, Battin MR, Moore MP. Metformin versus insulin for the treatment of gestational diabetes. N. Engl. J. Med.358(19), 2003–2015 (2008).
   PubMed Web of Science ®Google Scholar
• Jakubowicz DJ, Seppala M, Jakubowicz S et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin-like growth factor-binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab.86(3), 1126–1133 (2001).
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Pranikoff J, Aregawi D, Wang P. Prevention of gestational diabetes by metformin plus diet in patients with polycystic ovary syndrome. Fertil. Steril.89(3), 625–634 (2008).
   PubMed Web of Science ®Google Scholar
• Azziz R, Ehrmann D, Legro RS et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J. Clin. Endocrinol. Metab.86(4), 1626–1632 (2001).
   PubMed Web of Science ®Google Scholar
• Aroda VR, Ciaraldi TP, Burke P et al. Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial. J. Clin. Endocrinol. Metab.94(2), 469–476 (2009).
   PubMed Web of Science ®Google Scholar
• Tarkun I, Cetinarslan B, Turemen E, Sahin T, Canturk Z, Komsuoglu B. Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome. Eur. J. Endocrinol.153(1), 115–121 (2005).
   PubMed Web of Science ®Google Scholar
• Romualdi D, Guido M, Ciampelli M et al. Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Hum. Reprod.18(6), 1210–1218 (2003).
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Moreira A, Goldenberg N, Sieve L, Wang P. Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Hum. Reprod.18(8), 1618–1625 (2003).
   PubMed Web of Science ®Google Scholar
• Glintborg D, Andersen M, Hagen C, Heickendorff L, Hermann AP. Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J. Clin. Endocrinol. Metab.93(5), 1696–1701 (2008).
   PubMed Web of Science ®Google Scholar
• Karalliedde J, Buckingham RE. Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies. Drug Saf.30(9), 741–753 (2007).
   PubMed Web of Science ®Google Scholar
• Hermansen K, Mortensen LS. Bodyweight changes associated with antihyperglycaemic agents in Type 2 diabetes mellitus. Drug Saf.30(12), 1127–1142 (2007).
   PubMed Web of Science ®Google Scholar
• Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study. Hum. Reprod.21(6), 1400–1407 (2006).
   PubMed Web of Science ®Google Scholar
• Brettenthaler N, De Geyter C, Huber PR, Keller U. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.89(8), 3835–3840 (2004).
   PubMed Web of Science ®Google Scholar
• Practice Committee of the American Society for Reproductive Medicine. Use of clomiphene citrate in women. Fertil. Steril.86(5 Suppl. 1), S187–S193 (2006).
   Google Scholar
• Monography: clomiphene citrate. (2009).
   Google Scholar
• Eijkemans MJ, Imani B, Mulders AG, Habbema JD, Fauser BC. High singleton live birth rate following classical ovulation induction in normogonadotrophic anovulatory infertility (WHO 2). Hum. Reprod.18(11), 2357–2362 (2003).
   PubMed Web of Science ®Google Scholar
• Badawy A, Inany H, Mosbah A, Abulatta M. Luteal phase clomiphene citrate for ovulation induction in women with polycystic ovary syndrome: a novel protocol. Fertil. Steril.91(3), 838–841 (2009).
   PubMed Web of Science ®Google Scholar
• Legro RS, Barnhart HX, Schlaff WD et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N. Engl. J. Med.356(6), 551–566 (2007).
   PubMed Web of Science ®Google Scholar
• Homburg R. Clomiphene citrate – end of an era? A mini-review. Hum. Reprod.20(8), 2043–2051 (2005).
   PubMed Web of Science ®Google Scholar
• Messinis IE. Ovulation induction: a mini review. Hum. Reprod.20(10), 2688–2697 (2005).
   PubMed Web of Science ®Google Scholar
• The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Hum. Reprod.23(3), 462–477 (2008).
   PubMed Web of Science ®Google Scholar
• Imani B, Eijkemans MJ, te Velde ER, Habbema JD, Fauser BC. Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J. Clin. Endocrinol. Metab.83(7), 2361–2365 (1998).
   PubMed Web of Science ®Google Scholar
• Kousta E, White DM, Franks S. Modern use of clomiphene citrate in induction of ovulation. Hum. Reprod. Update3(4), 359–365 (1997).
   PubMed Web of Science ®Google Scholar
• Palomba S, Orio F Jr, Falbo A, Russo T, Tolino A, Zullo F. Clomiphene citrate versus metformin as first-line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.92(9), 3498–3503 (2007).
   PubMed Web of Science ®Google Scholar
• Palomba S, Orio F Jr, Falbo A et al. Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.90(7), 4068–4074 (2005).
   PubMed Web of Science ®Google Scholar
• Neveu N, Granger L, St Michel P, Lavoie HB. Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction and achievement of pregnancy in 154 women with polycystic ovary syndrome. Fertil. Steril.87(1), 113–120 (2007).
   PubMed Web of Science ®Google Scholar
• Balen A. Surgical treatment of polycystic ovary syndrome. Best Pract. Res. Clin. Endocrinol. Metab.20(2), 271–280 (2006).
   PubMed Web of Science ®Google Scholar
• Bayram N, van Wely M, Kaaijk EM, Bossuyt PM, van der Veen F. Using an electrocautery strategy or recombinant follicle stimulating hormone to induce ovulation in polycystic ovary syndrome: randomised controlled trial. BMJ328(7433), 192 (2004).
   PubMedGoogle Scholar
• Farquhar C, Lilford R, Marjoribanks J, Vanderkerchove P. Laparoscopic ‘drilling’ by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. The Cochrane Collaboration. John Wiley & Sons Ltd, NJ, USA (2009).
   Google Scholar
• Gurgan T, Urman B, Aksu T, Yarali H, Develioglu O, Kisnisci HA. The effect of short-interval laparoscopic lysis of adhesions on pregnancy rates following Nd-YAG laser photocoagulation of polycystic ovaries. Obstet. Gynecol.80(1), 45–47 (1992).
   PubMed Web of Science ®Google Scholar
• Amer SA, Banu Z, Li TC, Cooke ID. Long-term follow-up of patients with polycystic ovary syndrome after laparoscopic ovarian drilling: endocrine and ultrasonographic outcomes. Hum. Reprod.17(11), 2851–2857 (2002).
   PubMed Web of Science ®Google Scholar
• Api M. Is ovarian reserve diminished after laparoscopic ovarian drilling? Gynecol. Endocrinol.25(3), 159–165 (2009).
   PubMed Web of Science ®Google Scholar
• Palomba S, Orio F Jr, Nardo LG et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: a prospective parallel randomized double-blind placebo-controlled trial. J. Clin. Endocrinol. Metab.89(10), 4801–4809 (2004).
   PubMed Web of Science ®Google Scholar
• Kocak I, Ustun C. Effects of metformin on insulin resistance, androgen concentration, ovulation and pregnancy rates in women with polycystic ovary syndrome following laparoscopic ovarian drilling. J. Obstet. Gynaecol. Res.32(3), 292–298 (2006).
   PubMed Web of Science ®Google Scholar
• Zhu WJ, Li XM, Chen XM, Lin Z, Zhang L. Transvaginal, ultrasound-guided, ovarian, interstitial laser treatment in anovulatory women with clomifene-citrate-resistant polycystic ovary syndrome. BJOG113(7), 810–816 (2006).
   PubMed Web of Science ®Google Scholar
• Gordts S, Gordts S, Puttemans P, Valkenburg M, Campo R, Brosens I. Transvaginal hydrolaparoscopy in the treatment of polycystic ovary syndrome. Fertil. Steril.91(6), 2520–2526 (2009).
   PubMed Web of Science ®Google Scholar
• Homburg R, Howles CM. Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, results, reflections and refinements. Hum. Reprod. Update5(5), 493–499 (1999).
   PubMed Web of Science ®Google Scholar
• Christin-Maitre S, Hugues JN; Recombinant FSH Study Group. A comparative randomized multicentric study comparing the step-up versus step-down protocol in polycystic ovary syndrome. Hum. Reprod.18(8), 1626–1631 (2003).
   PubMed Web of Science ®Google Scholar
• Hugues JN, Cedrin-Durnerin I, Howles CM et al. The use of a decremental dose regimen in patients treated with a chronic low-dose step-up protocol for WHO group II anovulation: a prospective randomized multicentre study. Hum. Reprod.21(11), 2817–2822 (2006).
   PubMed Web of Science ®Google Scholar
• Hamilton-Fairley D, Kiddy D, Watson H, Paterson C, Franks S. Association of moderate obesity with a poor pregnancy outcome in women with polycystic ovary syndrome treated with low dose gonadotrophin. Br. J. Obstet. Gynaecol.99(2), 128–131 (1992).
   PubMedGoogle Scholar
• Orvieto R, Homburg R. Chronic ultra-low dose follicle-stimulating hormone regimen for patients with polycystic ovary syndrome: one click, one follicle, one pregnancy. Fertil. Steril.91(4 Suppl.), 1533–1535 (2009).
   PubMed Web of Science ®Google Scholar
• McCormick B, Thomas M, Maxwell R, Williams D, Aubuchon M. Effects of polycystic ovarian syndrome on in vitro fertilization-embryo transfer outcomes are influenced by body mass index. Fertil. Steril.90(6), 2304–2309 (2008).
   PubMed Web of Science ®Google Scholar
• van Santbrink EJ, Fauser BC. Is there a future for ovulation induction in the current era of assisted reproduction? Hum. Reprod.18(12), 2499–2502 (2003).
   PubMed Web of Science ®Google Scholar
• Papanikolaou EG, Camus M, Kolibianakis EM, Van Landuyt L, van Steirteghem A, Devroey P. in vitro fertilization with single blastocyst-stage versus single cleavage-stage embryos. N. Engl. J. Med.354(11), 1139–1146 (2006).
   PubMed Web of Science ®Google Scholar
• Kumbak B, Kahraman S. Efficacy of metformin supplementation during ovarian stimulation of lean PCOS patients undergoing in vitro fertilization. Acta Obstet. Gynecol. Scand.88(5), 563–568 (2009).
   PubMed Web of Science ®Google Scholar
• Tso LO, Costello MF, Albuquerque LE, Andriolo RB, Freitas V. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst. Rev. (2), CD006105 (2009).
   Google Scholar
• Farquhar C, Lee O, Toomath R, Jepson R. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database Syst. Rev. (4), CD000194 (2003).
   Google Scholar
• van der Spuy ZM, le Roux PA. Cyproterone acetate for hirsutism. Cochrane Database Syst. Rev. (4), CD001125 (2003).
   Google Scholar
• Swiglo BA, Cosma M, Flynn DN et al. Antiandrogens for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. J. Clin. Endocrinol. Metab.93(4), 1153–1160 (2008).
   PubMed Web of Science ®Google Scholar
• Calaf J, Lopez E, Millet A et al. Long-term efficacy and tolerability of flutamide combined with oral contraception in moderate to severe hirsutism: a 12-month, double-blind, parallel clinical trial. J. Clin. Endocrinol. Metab.92(9), 3446–3452 (2007).
   PubMed Web of Science ®Google Scholar
• Martin KA, Chang RJ, Ehrmann DA et al. Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab.93(4), 1105–1120 (2008).
   PubMed Web of Science ®Google Scholar
• Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet. Gynecol. Scand.71(8), 599–604 (1992).
   PubMed Web of Science ®Google Scholar
• Berneis K, Rizzo M, Hersberger M et al. Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome. Int. J. Clin. Pract.63(1), 56–62 (2009).
   PubMed Web of Science ®Google Scholar
• Moghetti P, Castello R, Negri C et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J. Clin. Endocrinol. Metab.85(1), 139–146 (2000).
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Spina G, Kouli C, Migdalis I. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J. Clin. Endocrinol. Metab.86(10), 4666–4673 (2001).
   PubMed Web of Science ®Google Scholar
• Morin-Papunen L, Rautio K, Ruokonen A, Hedberg P, Puukka M, Tapanainen JS. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.88(10), 4649–4654 (2003).
   PubMed Web of Science ®Google Scholar
• Luque-Ramirez M, Alvarez-Blasco F, Botella-Carretero JI, Martinez-Bermejo E, Lasuncion MA, Escobar-Morreale HF. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. J. Clin. Endocrinol. Metab.92(7), 2453–2461 (2007).
   PubMed Web of Science ®Google Scholar
• Romualdi D, Costantini B, Selvaggi L et al. Metformin improves endothelial function in normoinsulinemic PCOS patients: a new prospective. Hum. Reprod.23(9), 2127–2133 (2008).
   PubMed Web of Science ®Google Scholar
• Topcu S, Tok D, Caliskan M et al. Metformin therapy improves coronary microvascular function in patients with polycystic ovary syndrome and insulin resistance. Clin. Endocrinol. (Oxf.)65(1), 75–80 (2006).
   PubMed Web of Science ®Google Scholar
• Orio F Jr, Palomba S, Cascella T et al. Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. J. Clin. Endocrinol. Metab.90(11), 6072–6076 (2005).
   PubMed Web of Science ®Google Scholar
• Goldenberg N, Glueck CJ, Loftspring M, Sherman A, Wang P. Metformin-diet benefits in women with polycystic ovary syndrome in the bottom and top quintiles for insulin resistance. Metabolism54(1), 113–121 (2005).
   PubMed Web of Science ®Google Scholar
• Fleming R, Hopkinson ZE, Wallace AM, Greer IA, Sattar N. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J. Clin. Endocrinol. Metab.87(2), 569–574 (2002).
   PubMed Web of Science ®Google Scholar
• Ehrmann DA, Schneider DJ, Sobel BE et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.82(7), 2108–2116 (1997).
   PubMed Web of Science ®Google Scholar
• Sathyapalan T, Kilpatrick ES, Coady AM, Atkin SL. The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. J. Clin. Endocrinol. Metab.94(1), 103–108 (2009).
   PubMed Web of Science ®Google Scholar
• Carpentier AC. Postprandial fatty acid metabolism in the development of lipotoxicity and Type 2 diabetes. Diabetes Metab.34(2), 97–107 (2008).
   PubMed Web of Science ®Google Scholar
• Baillargeon JP. Insulin action in polycystic ovary syndrome: in vivo and in vitro. In: The Polycystic Ovary Syndrome – Current Concepts on Pathogenesis and Clinical Care. Azziz R (Ed.). Springer, NY, USA, 43–68 (2007).
   Google Scholar
• Baillargeon J-P, Diamanti-Kandarakis E, Ostlund REJ, Apridonidze T, Iuorno MJ, Nestler JE. Altered -chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care29(2), 300–305 (2006).
   PubMed Web of Science ®Google Scholar
• Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G. Ovulatory and metabolic effects of -chiro-inositol in the polycystic ovary syndrome. N. Engl. J. Med.340(17), 1314–1320 (1999).
   PubMed Web of Science ®Google Scholar
• Papaleo E, Unfer V, Baillargeon JP et al. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecol. Endocrinol.23(12), 700–703 (2007).
   PubMed Web of Science ®Google Scholar
• Genazzani AD, Lanzoni C, Ricchieri F, Jasonni VM. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol. Endocrinol.24(3), 139–144 (2008).
   PubMed Web of Science ®Google Scholar
• Bahceci M, Aydemir M, Tuzcu A. Effects of oral fat and glucose tolerance test on serum lipid profile, apolipoprotein, and CRP concentration, and insulin resistance in patients with polycystic ovary syndrome. Fertil. Steril.87(6), 1363–1368 (2007).
   PubMed Web of Science ®Google Scholar
• Chavez JA, Summers SA. Characterizing the effects of saturated fatty acids on insulin signaling and ceramide and diacylglycerol accumulation in 3T3-L1 adipocytes and C2C12 myotubes. Arch. Biochem. Biophys.419(2), 101–109 (2003).
   PubMed Web of Science ®Google Scholar
• Chavarro JE, Rich-Edwards JW, Rosner BA, Willett WC. Dietary fatty acid intakes and the risk of ovulatory infertility. Am. J. Clin. Nutr.85(1), 231–237 (2007).
   PubMed Web of Science ®Google Scholar
• Kasim-Karakas SE, Almario RU, Gregory L, Wong R, Todd H, Lasley BL. Metabolic and endocrine effects of a polyunsaturated fatty acid-rich diet in polycystic ovary syndrome. J. Clin. Endocrinol. Metab.89(2), 615–620 (2004).
   PubMed Web of Science ®Google Scholar
• Douglas CC, Norris LE, Oster RA, Darnell BE, Azziz R, Gower BA. Difference in dietary intake between women with polycystic ovary syndrome and healthy controls. Fertil. Steril.86(2), 411–417 (2006).
   PubMed Web of Science ®Google Scholar